Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evidence at Molecular Level Supports Link Between Environmental Estrogens and Breast Cancer

September 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 9
Volume 11
Issue 9

Data from two studies presented at the 88th Annual Meeting of the American Association for Cancer Research (AACR)

Data from two studies presented at the 88th Annual Meeting of the AmericanAssociation for Cancer Research (AACR) have added evidence to support anassociation between environmental estrogens and breast cancer. Lifetimeexposure to endogenous estrogens is known to be a risk factor for breastcancer. However, there is uncertainty about whether environmental estrogenssuch as DDT are definitively linked to breast cancer. Two large epidemiologicalstudies conducted in the 1990s produced conflicting findings regardingthe correlation between increasing concentrations of DDT metabolites andincidence of breast cancer. Moreover, little is known about the potentialmechanisms by which endogenous or environmental estrogens convert normalbreast epithelial cells into abnormal cells.

Scientists from the Karmanos Cancer Institute in Detroit examined theeffects of estradiol and five closely related organochlorine pesticideson cell growth in two estrogen receptor-positive human breast epithelialcell lines: precancerous cells and human breast cancer cells. Organochlorinepesticides have been associated with the development of breast cancer becauseof their estrogenic properties. Those selected for this study act as estrogenswith actions mediated through the estrogen receptor.

Pesticide Combinations More Lethal

Using a special assay, the investigators found that when the pesticideswere administered individually, they caused the human breast epithelialcells to proliferate, but only when they were administered at 100- to 1,000-foldhigher levels than estradiol. However, when the pesticides were administeredin combination, they caused cell proliferation similar to that observedwith physiological concentrations of estradiol.

According to study investigator, Malathy Shekhar, PhD, "To date,there is no conclusive proof that endogenous estrogens cause breast cancer.The only evidence comes from epidemiological studies showing an associationbetween an individual's total cumulative exposure to estrogen and breastcancer. In order to provide stronger evidence for this association, westudied the possible mechanisms by which estrogens cause malignancy. Weused an estrogen receptor-positive precancerous cell line that we developed."

Dr. Shekhar added, "We found that estradiol and the pesticidesactivated estrogen-mediated responses via estrogen receptors on this cellline, suggesting that some environmental estrogens, particularly in combination,may be involved in breast cancer progression. This is an important findingbecause environmental estrogens such as DDT still pose a threat to humanseven though their use has been banned for many years. Not only does DDTremain in the environment for many years, but it also concentrates in adiposetissue in the breast and other organs in the body."

In a second study reported at the AACR Annual Meeting, researchers atthe University of Rochester School of Medicine and Dentistry investigatedwhether DDT isomers, different chemical forms of DDT, and their metabolitescan bind to and activate estrogen receptors in humans and act as estrogens.Results from previous studies had indicated that certain DDT compoundsspecifically bind to and activate rodent and avian estrogen receptors,but no data have been available on how these compounds interact with thehuman estrogen receptor at the molecular level.

Rat vs Human Receptors

Experiments conducted by researchers at the University of RochesterSchool of Medicine and Dentistry measured the ability of DDT isomers andmetabolites to bind to and activate the human estrogen receptor. The studiesfound that many of the DDT compounds had more than 100-fold higher affinitiesfor the human estrogen receptor than for the rat estrogen receptor. Usinga cellular model that expresses human estrogen receptors and provides ameasurable signal when this receptor is activated, the researchers screenedthe DDT compounds for estrogenic activity. They found that the DDT isomersand metabolites that bound to the human estrogen receptor were able toactivate it in a concentration-dependent manner and elicit an additiveresponse when administered with another DDT metabolite or with estradiol.

According to study investigator, Clarice W. Chen, MS, "Of particularsignificance is the finding that both DDT isomers bind to the human estrogenreceptor, whereas only one binds with measurable affinity to the rat estrogenreceptor. Moreover, many DDT metabolites have a substantially higher affinityfor the human than the rat estrogen receptor, even though the main metaboliteof DDT does not. Our data suggest the metabolites that activate the humanestrogen receptor do so with the same potency as the parent compounds,and this activation is additive to that of another DDT compound or estradiol.These findings differ from those using other animal models and suggestthat humans may be more susceptible to DDT metabolites than other species."

Articles in this issue

UFT: East Meets West in Drug Development
UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support
Rationale for Phase I Study of UFT Plus Leucovorin and Oral JM-216
Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
5-FU or UFT Combined With Leucovorin for Previously Untreated Metastatic Colorectal Cancer
UFT in Gastric Cancer: Current Status and Future Developments
Oral UFT and Leucovorin in Patients With Advanced Gastric Carcinoma
Oral UFT Plus Leucovorin in Patients With Relapsed or Refractory Colorectal Cancer
Postoperative Adjuvant Chemotherapy With Mitomycin C and UFT for Rectal Cancer
UFT Plus Leucovorin in Advanced Hepatobiliary Tumors and Pancreatic Adenocarcinomas
Experience With UFT in Japan
Future Directions in the Adjuvant Treatment of Colon Cancer
Current and Future Directions in Adjuvant Combined-Modality Therapy of Rectal Cancer
UFT Plus Cisplatin for Advanced Gastric Cancer
Phase I and Pharmacokinetic Evaluations of UFT Plus Oral Leucovorin

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Related Content

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

Virginia Kaklamani, MD, DSc;Giorgi Dzagnidze;Nicoleta Zenovia Antone;Anu Thummala;Mikheil Janjalia;Patricia Santi;Carlos Barrios;Mehmet Ali Nahit Sendur;Xiaoling Zhang;Angela Gambioli;Manuel Dominguez;Kathy Puyana Theall;Tomer Wasserman;William J. Gradishar, MD
June 12th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.